-
Another positive: Earlier this week, the U.S. Food and Drug Administration approved Cozaar for use in preventing stroke.
FORBES: For Merck, Steps In The Right Direction
-
Barbey at George Washington University points to these drugs as being more well-tried than newer drugs like Merck's Cozaar.
FORBES: Pharmaceuticals
-
Merck tried to show a similar claim for Cozaar but fell short.
FORBES: Reviving Novartis
-
Michael Krensavage at Raymond James, who has been bearish about Merck, notes that the data behind using Cozaar for stroke were published already.
FORBES: For Merck, Steps In The Right Direction
-
The company's Diovan hypertension drug is catching up to Merck's Cozaar.
FORBES: Reviving Novartis
-
For Cozaar, which is growing thanks to new studies that offer proof that the pill can extend the lives of heart patients, the news is good.
FORBES: Merck Stays On Target
-
If U.S. Zocor sales remain flat or decline only slightly, it will be much easier for earnings to grow on the backs of Cozaar, Singulair and Fosamax.
FORBES: For Merck, Steps In The Right Direction